159 related articles for article (PubMed ID: 26131572)
1. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.
Mueller SK; Altvater B; Chen C; Kailayangiri S; Ahlmann M; Dirksen U; Juergens H; Rossig C
Oncol Rep; 2013 Jun; 29(6):2348-54. PubMed ID: 23525469
[TBL] [Abstract][Full Text] [Related]
3. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
5. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
8. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
[TBL] [Abstract][Full Text] [Related]
11. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
12. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos D; Tan DS; Jones RL; Judson IR
Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
14. IGF-1R as an anti-cancer target--trials and tribulations.
Chen HX; Sharon E
Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
Heitzeneder S; Sotillo E; Shern JF; Sindiri S; Xu P; Jones R; Pollak M; Noer PR; Lorette J; Fazli L; Alag A; Meltzer P; Lau C; Conover CA; Oxvig C; Sorensen PH; Maris JM; Khan J; Mackall CL
J Natl Cancer Inst; 2019 Sep; 111(9):970-982. PubMed ID: 30698726
[TBL] [Abstract][Full Text] [Related]
16. Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.
Schlegel P; Feuchtinger T; Nitschke-Gérard C; Seidel UJ; Lang AM; Kyzirakos C; Teltschik HM; Ebinger M; Schumm M; Koscielniak E; Handgretinger R; Lang P
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S72-6. PubMed ID: 26039213
[TBL] [Abstract][Full Text] [Related]
17. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
[TBL] [Abstract][Full Text] [Related]
18. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy strategies for Ewing sarcoma.
Rossig C
Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
